Sign inJoin waitlistJoin the waitlist

Lucas Wong

Physician · Baylor Scott & White Medical Center - Baylor College of Medicine

Credentials: · · · · · ·

History

Baylor Scott & White Medical Center - Baylor College of Medicine
Present

University of Arizona College Medicine
1991–1994
University of North Carolina Hospitals
1990–1991
University of North Carolina Healthcare
1988–1991
University of Texas School of Medicine at San Antonio
1984–1988

Research

Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study
Journal of Clinical Oncology · 2008 · 476 citations
Peroxisome proliferator-activated receptor gamma activation can regulate beta-catenin levels via a proteasome-mediated and adenomatous polyposis coli-independent pathway
Journal of Biological Chemistry · 2004 · 118 citations
Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive…
Cancer Medicine · 2013 · 78 citations

EH
Evan Hersh
3 papers
Arundhati Rao
2 papers
Christopher Lieu
2 papers
DA
David Adelberg
2 papers
David Gerber
2 papers
EC
Elena Chiorean
2 papers
Jeremy Kortmansky
2 papers
JR
John Rinehart
2 papers
JC
Jorge Chaves
2 papers
Kristen Spencer
2 papers
Lowell Hart
2 papers
MM
Manuel Modiano
2 papers

Grants

Scott & White Community Clinical Oncology Program
National Cancer Institute · U10
Contact PI · $7.1M · Scott and White Memorial Hospital
1997–2013

Clinical trials

Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies
Principal investigator · Completed · Phase 1
Peregrine Pharmaceuticals
2005–2009
A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy
Site PI · Recruiting
Novartis Pharmaceuticals
2025–2033
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2027
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2025–2037